Efient 5 mg film-coated tablets.

DRUG2 trials

Sponsors

Rigshospitalet, Amsterdam UMC Stichting

Conditions

Acute coronary syndrome and chronic coronary syndromeMyocardial infarction

Phase 4

Reduced antithrombotic strategy for high bleeding risk patients with myocardial infarction treated with percutaneous coronary intervention - The Dan-DAPT trial

RecruitingCTIS2022-500125-32-00

RigshospitaletMyocardial infarction

Start: 2022-06-20Target: 2700Updated: 2025-11-18

Prasugrel Monotherapy Reduced dose in Acute and Chronic Coronary Syndrome Patients after Percutaneous Coronary Intervention

RecruitingCTIS2024-520351-24-00

Amsterdam UMC StichtingAcute coronary syndrome and chronic coronary syndrome

Start: 2025-11-13Target: 300Updated: 2025-10-09

Related Papers

Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.

2025-02-262 citations